A5056404979- RNA modifications and cancer
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- HER2/EGFR in Cancer Research
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- Myasthenia Gravis and Thymoma
- Lung Cancer Diagnosis and Treatment
- Breast Lesions and Carcinomas
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Risks and Factors
- Synthesis and biological activity
- Pituitary Gland Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Sarcoma Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Estrogen and related hormone effects
- Neutropenia and Cancer Infections
- Advanced Breast Cancer Therapies
Pontificia Universidad Católica de Chile
2007-2023
The University of Texas MD Anderson Cancer Center
2011-2013
University of Ottawa
2013
The University of Texas Southwestern Medical Center
2012
Enhancer of zeste homolog 2 (EZH2) promotes carcinogenesis by epigenetically silencing tumor suppressor genes. We studied EZH2 expression immunohistochemistry in a large series non-small cell lung carcinomas (NSCLC) association with characteristics and patient outcomes.EZH2 was analyzed 265 normal premalignant bronchial epithelia, 541 primary NSCLCs [221 squamous (SCC) 320 adenocarcinomas] 36 paired brain metastases. An independent set 91 adenocarcinomas also examined. statistically...
Induction of tumor cell senescence may explain the response a patient with BRAF kinase–impaired lung cancer to multikinase inhibitor dasatinib.
Abstract BACKGROUND: Lung adenocarcinoma is histologically heterogeneous and has 5 distinct histologic growth patterns: lepidic, acinar, papillary, micropapillary, solid. To date, there no consensus regarding the clinical utility of these patterns. METHODS: The authors performed a detailed semiquantitative assessment patterns 240 lung adenocarcinomas determined association with patients' clinicopathologic features, including recurrence‐free survival (RFS) overall (OS) rates. In subset...
Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also geographical variations in incidence mortality rates. As Chile has one of the highest rates within South America, we sought define molecular profile Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples clinical data were obtained from 224 patients, with subsets analyzed by tissue microarray (TMA; n = 90) next generation...
Breast cancer (BC) is the most common malignancy in women. We retrieved medical records from >2,000 Chilean BC patients over 1997-2018 period. The objective was to assess changes clinical presentation or prognosis of our throughout these 20 years practice. Although variables did not display significant variations, we observed a progressive increase stage IV this Our data showed that tumour III/IV HER2-enriched subtype tumours were associated with poorer prognosis. In contrast, found...
Gastric cancer (GC) is a complex and heterogeneous disease. In recent decades, The Cancer Genome Atlas (TCGA) the Asian Research Group (ACRG) defined GC molecular subtypes. Unfortunately, these systems require high-cost techniques consequently their impact in clinic has remained limited. Additionally, most of studies are based on European, Asian, or North American cohorts. Herein, we report classification Chilean patients into five subtypes, immunohistochemical (IHC) situ hybridization (ISH)...
Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal of digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern immunohistochemical markers than GIST. Inhibitors tyrosine kinases such as Imatinib or Sunitinib mainstay treatment in management advanced metastatic Complete pathological response to these agents is an extremely rare event, especially case EGIST due its more aggressive behavior reported. Here we describe a 61 years old...
Gastric cancer (GC) is the world's second-leading cause of neoplastic mortality. Genetic alterations, response to treatments, and mortality rates are highly heterogeneous across different regions. Within Latin America, GC leading death in Chile, affecting 17.6 per 100,000 people causing >3000 deaths/y. Clinical outcomes "one size fits all" therapies thus a better stratification patients may aid treatment response.The Cancer Task Force Chilean collaborative, noninterventional study that seeks...
Neuroendocrine tumors (NETs) are relatively rare and highly heterogeneous neoplasms. Despite this, recent studies from North America Central Europe have suggested an increase in incidence. In Latin America, NET data scarce scattered with only a few reporting registries. Our goal was to establish registry Chile. Here, we report the establishment our first 166 patients. We observed slight preponderance of males, median age at diagnosis 53 years overall survival 110 months. As anticipated, most...
Background: Pathological factors, based mainly on immunohistochemistry (IHC) and histological differentiation, are mostly used to differentiate breast cancer (BC) subtypes. Our present aim was describe the characteristics survival of a relapsing BC patient cohort clinico-pathologic subtypes determined for primary tumors. Methods: We clinico- pathological definition grade (HG), estrogen receptor (ER), progesterone (PgR),and epidermal growth factor type 2 (HER2) expression assessed by IHC....
Background: Lung cancer (LC) is the second leading cause of death in Chile, causing >3,000 deaths every year. Epidemiological LC data Chile scarce and scattered. Here, we aimed to quantify prevalence Epidermal Growth Factor Receptor (EGFR) gene mutations a Chilean center. These may identify individuals that could benefit from targeted therapies such as Tyrosine Kinase Inhibitors (TKIs). Methods: A total 1,405 Biopsies 1,381 patients were retrospectively analyzed retrieving clinical EGFR...
Background: Breast cancer (BC) is the leading cause of death for Chilean women.About 11% cases are triple-negative (TN) BC.These characterised by poor prognosis, higher risk early recurrence and visceral dissemination versus other BC subtypes.Current standard treatment early-stage non-metastatic TNBC patients consists neoadjuvant chemotherapy (NACT) followed surgery radiotherapy.Pathological complete response (pCR) to NACT associated with an increase in survival rates.In general, adjuvant...
Objective: Tumor response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients is a predictor for overall survival. The aim of our study was determine relationship between the neutrophil lymphocyte ratio (NLR) prior NAC, BC subtypes and probability pathologic complete (pCR). Materials Methods: Medical records were collected retrospectively from Centro de Cancer at Red Salud UC-Christus. Clinical data included peripheral blood cell counts, subtype diagnosis pathology report...
Introduction: Breast cancer can be classified into subtypes based on immunohistochemical markers, with Ki67 expression levels being used to divide luminal BC tumors in A and B subtypes; however, is not routinely determined due a lack of standardization. Objective: To evaluate histological grade Eliminate: the mitotic index determine if they as an alternative method staining for subtype definition. Methods: We evaluated estrogen receptor positive breast tissue samples. Pathological analysis...
Survival of patients with metastatic breast cancer according to pathological types tumorsBackground: The prognosis (BC) is in part determined by the stage at diagnosis and its characteristics.Aim: To evaluate association between survival women features tumor.Patients Methods: We obtained clinical data from diagnosed a BC 1999 2013.The expression estrogen (ER) progesterone (PR) receptors human epidermal growth factor receptor 2 (HER2) was immunohistochemistry. Clinicopathological subtypes...
Overall 5 years survival for surgically excised gastric cancer is 30%. Adjuvant treatment may improve the surgical results.To assess results and toxicity in patients with cancer, treated adjuvant radiotherapy concomitant continuous 5-Fluorouracil (5-FU).Forty one aged 32 to 73 (29 males) stage II-IVA subjected a total or subtotal gastrectomy D2 nodal dissection between 1997 2006, were studied. They received bed draining nodes dose of 50.4 Gy 28 fractions chemotherapy infusion 5-FU, 200...
Superior vena cava syndrome (SVCS) is caused by the obstruction of venous drainage from upper portion body. Common clinical findings are headache and cervical, facial limb edema. Occasionally, clouding consciousness appears.to report our experience with endovascular treatment SVCS.Retrospective review all patients SVCS subjected to between 1999 2005.Eight were treated, them malignancies. Six had a benign due presence chemotherapy catheter located in superior cava, one secondary radiation...
Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy) Background: Chemotherapy improves survival in cancer.However the most active combinations have a high level toxicity that limits their use.Aim: To assess response, and patients cancer, treated 5-fluorouracil/leucovorin chemotherapy).Material methods: Patients stage IV according to American Joint Committee on Cancer or relapsed disease functional capacity 0-2 South West Oncology...
Background: About 80% of breast cancer (BC) cases express estrogen receptor (ER), which has been correlated with good prognosis and response to deprivation
HER2+ breast cancer (BC) subtype overexpresses the Human Epidermal growth factor Receptor type-2 (HER2) and is characterized by its aggressiveness high sensitivity to monoclonal antibody-based HER2-targeted therapies.